ANX anadis limited

Anadis...New Development

  1. 12,939 Posts.
    lightbulb Created with Sketch. 75
    I mentioned this one yesterday for those interested in the contarian approach. ie biotechs have not exactly been doing well lately. This is the best time to buy of course. The question with biotechs given the long lead time and great risk is which one. It's a bit of a lottery in all honesty but I bought into ANX recently after looking closely at them. It will take a while but I believe they have potential.

    Chuck

    ANADIS LIMITED 2002-06-05 ASX-SIGNAL-G

    HOMEX - Melbourne

    +++++++++++++++++++++++++
    Anadis scientists have demonstrated a new technique, tentatively
    titled "Bioshielding", for delivering delicate molecules (such as
    vaccines and pharmaceuticals) to the stomach wall. This technology is
    an important breakthrough achieved through our work with H pylori
    vaccines. The applications for this technology has benefits not only
    for Anadis' products currently in development but also for a wide
    range of existing products needing to be delivered to the
    gastrointestinal tract in an active state.

    Preserving delicate molecules such as vaccine proteins to target the
    stomach wall has been impossible in the past because of the
    aggressive acid and digestive enzymes present which destroy any
    delicate molecule before it reaches its target. This breakthough
    means that direct drug treatment of the stomach lining is now
    possible. Many products that may have been shelved in the past by
    other drug developers because they were too delicate to survive the
    harsh environment around the stomach lining may now reach commercial
    reality.

    Anadis has lodged a provisional patent covering the work done to date
    and is actively pursuing further research to expand other
    applications for this platform technology. As new applications for
    the technology are created Anadis will further define the existing
    patent or lodge further patents for this discovery.


    C Graham
    MANAGING DIRECTOR & CEO

    For further information Contact:

    Conor Graham or Dr Grant Rawlin
    Telephone: 03 93586388
    Facsimile: 03 93586399
    Email: [email protected]



 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.